Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies

被引：1
|
作者：
Meringa, A. D. [1 ]
Hernandez-Lopez, P. [1 ]
Cleven, A. [1 ]
de Witte, M. [1 ,2 ]
Straetemans, T. [1 ,2 ]
Kuball, J. [1 ,2 ]
Beringer, D. X. [1 ]
Sebestyen, Z. [1 ]
机构：
[1] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands
[2] Univ Utrecht, Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands
来源：
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词：
T-cell therapy; gamma delta TCR; cancer; immune therapy; antigen; fitness; TME (tumor microenvironment); migration; ANTIGEN RECEPTOR; ANTITUMOR-ACTIVITY; 4-1BB COSTIMULATION; RECOGNITION; LYMPHOCYTES; TUMORS; STRESS; MICROENVIRONMENT; IMMUNOTHERAPY; CYTOKINE;
D O I：
10.3389/fimmu.2023.1159337
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Comprehensive Identification of Tumor-Reactive TCRs and Cognate Targets for Novel TCR T-Cell Cancer Therapies
    Wang, Yifan
    Ferretti, Andrew
    Nabilsi, Nancy
    Xu, Qikai
    Cristofaro, Alexander
    Weinheimer, Adam
    Jahan, Kenneth
    Zhang, Ruan
    MacBeath, Gavin
    MOLECULAR THERAPY, 2020, 28 (04) : 501 - 501
  • [32] Treatment strategies for peripheral T-cell lymphomas
    Foss, Francine M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (01) : 43 - 56
  • [33] Alemtuzumab in T-cell malignancies
    Claire E. Dearden
    Estella Matutes
    Daniel Catovsky
    Medical Oncology, 2002, 19 : S27 - S32
  • [34] Increasing responses to T-cell therapies in solid tumours by the use of an engineered adenovirus coding for TNFa and IL-2
    Cervera-Carrascon, V.
    Havunen, R.
    Santos, J. M.
    Quixabeira, D. C. A.
    Hemminki, A.
    Zafar, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] Alemtuzumab in T-cell malignancies
    Dearden, CE
    Matutes, E
    Catovsky, D
    MEDICAL ONCOLOGY, 2002, 19 (Suppl 2) : S27 - S32
  • [36] Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy
    Marar, Rosalyn I. I.
    Abbasi, Muhannad Aboud
    Prathivadhi-Bhayankaram, Sruti
    Daryanani, Andres
    Villarraga, Hector
    Anavekar, Nandan
    Bhatt, Vijaya Raj
    Paludo, Jonas
    JCO ONCOLOGY PRACTICE, 2023, 19 (06) : 331 - +
  • [37] Celyad's novel CAR T-cell therapy for solid malignancies
    Lonez, Caroline
    Hendlisz, Alain
    Shaza, Leila
    Aftimos, Philippe
    Vouche, Michae
    Donckier, Vincent
    Machiels, Jean-Pascal H.
    Van den Eynde, Marc
    Canon, Jean-Luc
    Carrasco, Javier
    Odunsi, Kunle
    Sahebjam, Solmaz
    Rottey, Sylvie
    Braun, Nathalie
    Verma, Bikash
    Gilham, David E.
    Lehmann, Frederic F.
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2018, 66 (02) : 53 - 56
  • [38] T-cell therapies for HIV: Preclinical successes and current clinical strategies
    Patel, Shabnum
    Jones, R. Brad
    Nixon, Douglas F.
    Bollard, Catherine M.
    CYTOTHERAPY, 2016, 18 (08) : 931 - 942
  • [39] Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy
    Nakamura, Tomoki
    Hasegawa, Masahiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [40] CD5 CAR for the Treatment of T-Cell Malignancies
    Mamonkin, Maksim
    Brenner, Malcolm K.
    MOLECULAR THERAPY, 2015, 23 : S162 - S163
12345